Reporter cell lines have been developed for the identification of inhibitors of gene expression enhanced by hypoxia-inducible factor 2, which has been implicated as a transcription factor involved in the tumorigenesis of clear cell renal carcinoma. Stably transformed reporter clones of the human renal clear cell carcinoma cell line 786-O were generated by transfection or retroviral infection. Luciferase reporter expression in the vectors used was driven by either the natural human vascular endothelial growth factor (VEGF) promoter-enhancer or by the VEGF and the human endothelial nitric oxide synthase enhancers modulating minimal human cytomegalovirus promoter. Utility of the generated reporter cell lines was validated by introducing the von Hippel-Lindau protein complex and testing for reporter inducibility by hypoxia. The dynamic range in reporter activity under hypoxic stress was found to be at least 30-to 40-fold, with a signal-to-noise ratio of 60:1. Properties of the cell lines such as tolerance to up to 3% DMSO, signal stability with multiple in vitro passages, and utility in both 96and 384-well plate formats indicated their suitability for use in a high-throughput screen. In addition, the potential use of these reporter lines in the evaluation of high-throughput screening hits in vivo in various mice models has been demonstrated.
O NE OF THE CELLULAR ADAPTIVE RESPONSES through which tumor cells respond to lowered oxygen content in their microenvironment is the hypoxia-inducible factor (HIF)-induced transcription of genes involved in diverse processes such as red blood cell production, angiogenesis, vascular tone, glycolysis, and cellular glucose uptake. In mediating these responses, HIF-1α and HIF-2α are known to dimerize with the aryl hydrocarbon receptor nuclear translocator (ARNT; also referred to as HIF-1β) to form HIF-1 and HIF-2, respectively. Regulation of the HIF-α-chain protein level is a primary determinant of HIF activity. Biochemical studies have shown that under normoxic conditions, HIF-α subunits are regulated through their interaction with the von Hippel-Lindau (VHL) tumor suppressor protein complex, which marks them for rapid degradation by the ubiquitin-proteasome system. 1, 2 In contrast, under hypoxic conditions, or, as in the case of the autosomal dominantly inherited familial cancer syndrome, VHL disease, the HIF-α proteins are stabilized and are free to form the heterodimer HIF, which in turn enhances the transcription of a number of downstream genes thought to be important in cancer.
Although HIF-1 and HIF-2 appear to overlap in the range of genes whose expressions they modulate, there appears to be little redundancy in function between the two. Recent studies have shown that HIF-1α and HIF-2α may have differential expression, distribution, and roles in normal and cancerous human cell populations and tissues. [3] [4] [5] [6] Significantly, HIF-2α mRNA expression has been found to be upregulated in hemangioblastomas of the CNS and retina, clear cell carcinomas of the kidney, and pheochromocytomas, which are the most common manifestations of VHL disease. 7 These data indicate that although HIF-2α may be present in a wide range of cells, it might play an important role in tumorigenesis. In fact, 786-O renal carcinoma cells, which lack functional VHL and HIF-1α protein but overproduce HIF-2α, were shown to form large tumors in nude mice, whereas wild-type VHL clones were unable to form tumors in these mice. 8 It has also been shown that 786-O cells with an HIF-2α variant that escapes VHL protein control are able to form tumors. 9 Furthermore, targeted replacement of HIF-1α by HIF-2α knock-in allele in embryonic stem cells was shown to promote tumor growth. 10 Short hairpin RNA-mediated inactivation of HIF-2α has been shown to phenocopy the effects of reintroduction of the VHL gene in the 786-O cell line, causing a decrease in the expression of hypoxia-inducible genes in vitro and tumor growth suppression in vivo. These results indicate that HIF-2 is potentially a critical target for small-molecule inhibitors in VHL disease. 11 To date, various compounds have been identified as being inhibitors of HIF-1-induced transcriptional activation. These include the Topo-I inhibitor topotecan and 2 of its analogs, NSC606985 and NSC639174 12 ; the Hsp90 antagonist geldanamycin and its analog 17-AAG 13 ; NSC134754 and NSC643735 14 ; the podophyllotoxin derivative GL331 15 ; the histone deacetylase inhibitor FK228 16 ; the hypoxic cytotoxin TX-402 17 ; the Chaetomium fungal metabolite chetomin 18 ; and various flavonoids. 19 However, with the exception of the nonsteroidal anti-inflammatory drug ibuprofen, no other small molecule has been reported to inhibit HIF-2 activity. 20 Furthermore, the effect of these compounds on transcriptional activation by other HIF isoforms in particular and transcriptional activation in general has also yet to be clearly delineated. Here, we describe the development of a cell-based screening assay for the identification of inhibitors of HIF-2.
MATERIALS AND METHODS

Materials
Actinomycin D, ibuprofen, camptothecin, luteolin, quercetin, resveratrol, cylcoheximide, LY294-002, rapamycin, IGEPAL CA-650, phenazine methosulfate (PMS), and DMSO were obtained commercially from Sigma (St. Louis, MO). NSC254681, NSC359449, NSC606985, NSC607097, NSC639174, and NSC675865 were obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. 3-Nitro-4-[(4-nitro-1,2,5-oxadiazol-3-yl)methoxy]-1,2,5-oxadiazole (NNMO) was obtained commercially from Hit2Lead (San Diego, CA). Reporter readout in various experiments was obtained in either 96-or 384-well white microplates (#9502887 and #164610, respectively; Thermo Electron, Vantaa, Finland) or 384-well white plates (#6007688; Perkin-Elmer, Boston, MA).
Cloning of HRE-Luc and VHL constructs
The destabilized enhanced green fluorescent protein with a 4-h half-life (d4EGFP) gene in the vector pd4EGFP-N1 (Clontech, Mountain View, CA) was replaced by the BamHI-NotI firefly luciferase gene (Luc + ) fragment digested out of the pGL3 vector (Promega, Madison, WI) to give rise to the pLLuc construct. The vector backbone for the rest of the luciferase constructs was generated by removal of the cytomegalovirus (CMV) promoter from the vector pd4EGFP-N1 using AseI and BglII. Following this, a 1.9-kb fragment comprising a multiple cloning site and either the minimal simian virus 40 promoter (SV40mp) or the minimal human CMV promoter (hCMVmp) and a downstream luciferase gene were inserted between EcoRI and NotI sites of this plasmid to generate 2 versions of pMCS-Luc, with one having SV40mp and the other hCMVmp. The plasmid pVHRE-Luc was generated by inserting a 1128-bp natural enhancer-promoter fragment of the human vascular endothelial growth factor (VEGF) gene (sequence starting from 1291 and ending at 2418 using the numbering system of GenBank, accession no. M63971) between the EcoRI and KpnI sites of pMCS-Luc, replacing the minimal promoter present. This 1128-bp fragment of the VEGF promoter was obtained by PCR using the forward primer 5′-AGTCCCTGGCAACATCTG-3′ and reverse primer 5′-TGATAGCCCCCAGCGCCACG-3′ from the plasmid pVR47/CAT. 21 A 225-bp fragment comprising 5 copies of the 41-bp HIF recognition sequence of the human endothelial nitric oxide synthase gene linked in tandem by a 5-bp linker (5xNHRE), was synthetically generated. 21, 22 Similarly, a 195-bp fragment was generated using the 35-bp HIF recognition sequence of the VEGF gene (5xVHRE). 21 Insertion of these multiple hypoxia response elements (HREs) between EcoRI and MluI sites of pMCS-Luc gave the plasmids p5xNHRE-Luc and p5xVHRE-Luc, respectively. These 2 constructs each had 2 versions, with one having SV40mp (5xHRE-SV40mp) and the other hCMVmp (5xHRE-hCMVmp).
To obtain the pQVHL-II construct, the human VHL open reading frame was amplified by PCR from the plasmid pSPORT-VHL by adding a kozak sequence prior to the transcription start site in the sense primer to optimize VHL expression. 23 This cDNA was then subcloned between BsiWI and PacI sites of the retroviral plasmid pQCXIH (Clontech). Sequences for all constructs were confirmed by both restriction analysis and sequencing using BigDyeTerminator (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol.
Transfection and transformation
The human renal clear cell carcinoma cell line 786-O and breast carcinoma cell line MDA-MB-435 were transfected with luciferase constructs using Fugene 6 (Roche, Indianapolis, IN) transfection reagent following the manufacturer's protocol to generate LLuc, MCS-Luc, VHRE-Luc, 5xVHRE-Luc, and 5xNHRE-Luc lines. To generate wild-type VHL lines and empty vector control lines, AmphoPak-293 (Clontech) packaging cell lines were first transfected with the pQVHL-II or pQCXIH retroviral constructs, respectively, using Fugene 6 reagent. Stable transfection of these packaging cell lines was supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen) and penicillin-streptomycin (at 100 IU/mL and 100 µg/mL, respectively; Biosource, Camarillo, CA). G418 (0.75 µg/ml; Mediatech, Herndon, VA), hygromycin B (200 µg/mL), or a combination of both was used for routine selection and maintenance of cell lines. Cell cultures were then maintained at 37 °C in a humidified incubator under a 5% CO 2 , 20% O 2 atmosphere. For hypoxic induction experiments, cells were cultured in 15-cm plates placed in a seamless fiberglass hypoxia chamber (Fisher Scientific, Pittsburgh, PA) equilibrated with 0.5% O 2 , 5% CO 2 , 94% N 2 atmosphere (Roberts Oxygen Co., Gaithersburg, MD). The chamber was tested for leaks under positive pressure using a bubble-forming agent (SNOOP; Nupro Co., Willoughby, OH) and was shown to hold a 3 psi charge for 48 h.
Prior to exposure to compounds, cells were harvested by trypsinization, spun down, and resuspended in phenol red-free Ham's F-12 or DMEM supplemented with 10% FBS. Plates were seeded at 50,000 cells per well in 50 µL medium for 96-well plates and at 5000 cells per well in 27 µL medium for 384-well plates using a µFill microplate liquid dispenser (BioTek, Winooski, VT) and incubated overnight before compound treatment. Stock solutions (25 mM) of the test compounds were prepared in DMSO, and appropriate amounts were aliquoted into Ham's F-12-based medium to prepare test compound dilutions at 10 times the final concentrations, ranging between 4 mM and 200 pM. For compound treatment, 3 µL of test compounds in culture medium was added into each well using a Biomek FX (Beckman Coulter, Fullerton CA) automated liquid-handling workstation. Final DMSO concentrations per well were below 0.5%. A total of 30 µL SteadyLite luciferase assay reagent (#6016987; PerkinElmer, Boston, MA) was added to each well using a µFill microplate dispenser, and luminescence measurements were made after 15 min of incubation at room temperature.
Growth rate and cytotoxicity test
After the 24-h incubation with test compounds or DMSO controls, cells in 384-well plates were exposed to 10 µL of the test medium containing 0.1% 2,3-bis[2-methoxy-4nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT, Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute) and 0.63% PMS in an incubator for 2 h at 37 °C. Viable cells reduced the tetrazolium salt to a colored formazan product. Once the incubation was completed, the plates were then read at 450 nm (with an integration time of 0.1 s/well) using a Victor 2 1420 multilabel counter (PerkinElmer).
Luminescence measurements
Luminescence measurements were carried out at 25 °C in an IVIS imaging system using a chilled CCD (Xenogen Corp., Alameda, CA). An exposure time of 15 to 30 s with an on-chip binning of 5 (i.e., 25 adjacent pixels [a 5 × 5 square] were combined to generate 1 pixel) was used during image acquisition. Luminescence was quantified by summing pixel intensities within each cell of a 96-or 384-celled grid after background subtraction. Results of experiments with test compounds were read using a Victor 2 1420 multilabel counter with an integration time of 1 s.
Real-time reverse transcription-PCR analysis
786-O pQVHL-II, 786-O pQ, and MDA-MB-435 were harvested separately using trizol (Life Technologies, Gaithersburg, MD) to isolate total RNA as described earlier. 23 Reverse transcription-PCR (RT-PCR) was performed using a TaqMan reverse transcription kit (Applied Biosystems, Foster City, CA) following the manufacturer's protocol on 2 µg of total RNA using the temperature program 10 min at 25 °C, 30 min at 48 °C, and finally 5 min at 95 °C. Relative expression of human VHL, VEGF, and Glut-I was determined in real-time PCR using an ABI-Prism 7700 sequence detection system. RT-PCR was performed in triplicate per sample following the temperature program 2 min at 50 °C and 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. The primers and probes used were all commercially obtained from Applied Biosystems. Relative quantitation of gene expression was determined using the comparative (∆∆CT) method. 24 Here, β-actin was used as an internal control.
Western blot analysis
Plates 15 cm in size containing about 80% confluent cultures were washed with phosphate-buffered saline (PBS), scraped, and centrifuged to pellet the cells. The cell pellets were lysed for 30 min at 4 °C with a buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 20 µg/mL protease inhibitor cocktail (Roche, Indianapolis, IN), 10 mM EDTA, 1% IGEPAL CA-650, 1 mM Na 3 VO 4 , and 1 mM NaF. The protein content of the clarified lysates was determined by Bradford assay (Bio-Rad, Hercules, CA). For VHL and HIF-1α and HIF-2α expression analyses, 20 µg of protein was loaded per lane, resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA). HIF blots were first probed with either monoclonal anti-HIF-1α (1:500; BD Pharmingen, San Diego, CA) or polyclonal anti-HIF-2α (1:500; Abcam, Cambridge, MA) antibodies. After stripping, the membrane was probed for HIF-1β as a loading control. The VHL blot was probed with monoclonal mouse anti-VHL antibody (1:333; BD Pharmingen). Following incubation with primary antibody, membranes were washed and incubated with horseradish-peroxidase-conjugated secondary antibody (Jackson Lab, Bar Harbor, ME) and developed using ECL Western blotting detection reagent (Amersham Biosciences, Piscataway, NJ).
2-day plate uniformity and signal variability assessment
A study was run over 2 days with 3 plates per day to assess plate uniformity and signal-to-noise ratio, using DMSO at the concentration to be used in screening. Variability tests were conducted on 3 types of signals. The maximum signal was obtained by treating wells with medium containing only DMSO (shown as "max" in Fig. 6) . To obtain the minimum signal, wells were treated with 0.025 µg/mL of NNMO, a non-HIFspecific inhibitor found to inhibit reporter signal to near background levels (shown as "min" in Fig. 6 ). To estimate signal variability at points between the maximum and minimum signals, actinomycin D was used at a concentration of 0.5 µg/mL (shown as "mid" in Fig. 6 ). On plate 1 on both days, columns 1, 2, and 3 received max, mid, and min treatments, respectively. This was then repeated 8 times through the last column. The treatment order on plate 2 was Min → Max → Mid, whereas that on plate 3 was Mid → Min → Max. Results were analyzed by plotting the signal from each well against the well number, in which the wells are ordered either by row first then by column or by column first and then by row. 25
In vivo bioluminescence imaging
In vivo bioluminescence imaging was conducted with a Xenogen IVIS imaging system using Living Image acquisition and analysis software (Xenogen). D-Luciferin (potassium salt; Xenogen) was dissolved to 15 mg/mL in PBS, filter sterilized, and stored at -20 °C. Strict animal care was provided in accordance with the procedures set forth in the Guide for the Care and Use of Laboratory Animals. 26 Animals used in these studies were male, SCID-beige mice, 4 to 10 weeks old (Taconic Farms, Germantown, MD). Mice were anesthetized with isofluorane and subsequently received an intraperitoneal injection with luciferin (150 mg/kg body weight) in PBS. Images were acquired 10 min after luciferin administration. A photographic image of the mice was taken in the chamber under dim illumination, followed by acquisition and overlay of the pseudocolor image representing the spatial distribution of photon counts produced by active luciferase within the animal. An exposure time of 5 min with a binning of 5 was used for luminescent image acquisition. Signal intensity was quantified as the sum of all detected photon counts within the region of interest after subtraction of background luminescence measured at the dorsal trunk.
Data analysis
Data were collected from at least 2 independent experiments, with 3 or more replicates per experiment. An experiment was either a 96-or a 384-well plate that included 3 to 8 independent observations (wells) each of the vehicle control, test compounds, and background control (vehicle plus cells with minimal promoter without an enhancer). Results were analyzed with analysis of variance to determine the significance of treatment effects, using standard weighted-means analysis to examine differences between individual treatment groups. The level of significance was taken as p < 0.0001. Photon counts reported are counts above background value for each replicate for statistical analysis. Signal-to-noise ratios were calculated as . The Z′ factor was determined according to , where σ c is the standard deviation of the positive control (actinomycin D), σ b is the standard deviation of the negative control (test medium with DMSO), µ c is the mean of the positive control, and µ b is the mean of the negative control. 27 
RESULTS AND DISCUSSION
Generation of reporter constructs and cell lines
A cell-based reporter assay strategy was chosen as an alternative to commonly used cell-free systems because of our interest in identifying inhibitors of HIF-2 in as close to
physiologically relevant conditions as possible. Therefore, one of the approaches we followed in designing the reporter constructs was the use of natural full-length promoters that provide a natural environment for the interaction with the HIF transcription complex. However, because high-throughput screening (HTS) assays often require a broad dynamic range and high signal-tonoise ratio, not usually attained by innate transcription, an alternative approach employing strong minimal promoters modulated by HIF-binding HRE fragments was also used in designing vectors. Consequently, we first evaluated the well-characterized hypoxia and HIF-2-responsive 1.1kb 5′ flanking region of the human VEGF gene. This natural VEGF promoter driving luciferase expression in a construct was used to generate stably transformed 786-O VHRE-Luc. In parallel, we also generated cell lines transformed by constructs having 5 copies of HREs of either the VEGF or the human endothelial nitric oxide synthase (heNOS) genes in tandem and ligated 5′ to a minimal promoter.
The various HRE reporter cell lines were generated through lipid-mediated DNA transfer followed by selection for neomycin resistance. In most cases, the transfection efficiency attained ranged between 30% and 60%. Upon stable transfection, the natural VEGF promoter-based reporter line (VHRE-Luc) was found to give rise to the lowest level of reporter activity from among the different reporter lines (Fig. 1) . In contrast, reporter lines transformed by constructs with 5 copies of HREs placed before either the SV40mp (5xNHRE-Luc) or hCMVmp (exVHRE-Luc) displayed a 40-and 50-fold increase in luciferase activity, respectively, over that shown by lines with the minimal promoter alone demonstrating a much enhanced dynamic range. Basal activity in 786-O MCS-Luc line (with either SV40mp or hCMVmp) was found to be just above background levels in these lines. The enhanced reporter activity seen in 786-O 5xVHRE-Luc (having either SV40mp or hCMVmp) reporter lines also translated into higher signal-tonoise ratios of 38:1 for the cell line with the SV40mp-based construct and 61:1 for the cell line with the hCMVmp-based construct. Thus, from among the different reporter cell lines, 786-O 5xHRE-Luc lines having the hCMVmp were selected for use in the assay.
Validation of constructs and clone selection
The 786-O cell line lacks functional VHL and stably expresses only HIF-2α. As a result, the reporter signal in 786-O 5xHRE-Luc lines is always "on." To demonstrate HIF-2α specific inducibility of the reporter in these lines, we first generated clones of the two 786-O 5xHRE-Luc lines and transformed these using the pQVHL-II construct to generate the VHL +/+ lines 786-O VHRE-WT and 786-O NHRE-WT. VHL protein expression in these lines was confirmed by Western blotting ( Fig. 2A) . RT-PCR results (Fig. 2B) also confirmed that VHL mRNA levels increased 38-fold on introduction of VHL, whereas mRNA levels of the known HIF-2 modulated genes GLUT-1 and VEGF were found to be 1.9-and 3.6-fold higher, respectively, in the VHL -/line. Furthermore, Western blotting also confirmed the presence of HIF-2α in 786-O VHRE-WT and HIF-1α in MDA-MB-435 under hypoxic conditions (Fig. 2C) .
Next, clones of 786-O VHRE-WT and 786-O NHRE-WT were incubated under hypoxic condition for 24 h. Reporter readout obtained at the end of this period was compared with that obtained from the same clones incubated in normoxia. Inducible clones suitable for further experiments were identified based on the results shown in Figure 3 . The maximum reporter expression as a result of hypoxic induction was found to be 40-fold, demonstrating the utility of the identified clones in HTS. Comparison of reporter inducibility by hypoxia among the different clones led to the selection of clone 124 of 786-O 5xVHRE-Luc and clone 92 of 5xNHRE-Luc lines for use in the screen. In addition, the physiologically relevant cutoff for screen hits was defined as 70% inhibition of the reporter activity. This was arrived at by comparing the decrease in reporter activity under hypoxia to that in normoxia of clone 124 of 786-O 5xVHRE-Luc after the reintroduction of the VHL gene in this clone.
Growth rate and seeding density
Growth characteristics of 786-O 5xNHRE-Luc and 5xVHRE-Luc cultures were assessed in microplates using DMEM and Ham's F-12-based media. Based on the results obtained using the XTT-based colorimetric proliferation assay, which measures the formation of a colored soluble bioreduction product generated by metabolically active cells, a doubling time of 24 to 36 h was determined in both media, indicating that both media were equally suited for growth.
FIG. 1. Comparison of reporter expression levels in 786-O cells transformed with luciferase reporter constructs containing various promoters.
Cells were plated at a concentration of 50,000 cells/well in a 96-well plate and incubated overnight. Luminescence signals were measured with a highly sensitive cryogenically-cooled CCD camera. The data are expressed as mean photon emission from luciferase activity ± SD.
Seeding densities between 1000 and 100,000 cells/well in 96-well plates and between 600 and 20,000 cells/well in 384-well plates were tested, and luciferase activity and signalto-noise ratios at each seeding density were compared. Luminescence intensity was found to increase proportionally to cell number in both 96-and 384-well plates, indicating that the signal intensity correlated directly with the number of cells per well (Fig. 4A, B) . However, comparison of signal-to-noise ratio at each tested cell concentration enabled the identification of the suitable seeding density. Based on this, a robust luminescent signal was achieved at 50,000 cells/well in 96-well plates and at 5000 cells/well in 384-well plates, with much smaller improvement in signal-to-noise ratio resulting beyond these concentrations. Thus, a seeding density of 5000 cells/well in a 384-well format was chosen to conduct the HTS campaign.
Cell culture characterization for HTS
In adopting any cell-based assay for HTS, consideration must always be given to such factors as the impact of passage number of the assay cell cultures, growth phase of cultures before harvesting, effect of culture medium on reporter readout, and tolerance of cells to organic solvents, as these may have an impact on the stability and reproducibility of the assay results. Therefore, preliminary studies addressing these parameters were carried out to identify optimal conditions under which the HTS assay can be performed. We first examined the effect of growth media on reporter readout. Background measurements using the 786-O MCS-Luc cell line in DMEM, phenol red-free DMEM, and phenol red-free Ham's F-12-based media showed that phenol red-free DMEM-based media had an acceptable level of background and thus was selected for use in the screen. The effect of passage number on reporter expression in the 786-O 5xVHRE-Luc was assessed by following reporter expression for up to 20 passages. The results indicated that reporter activity remained stable between passages 2 and 12, with reporter expression significantly decreasing with further passaging. Following this, reporter expression was then evaluated in assay plates seeded with cells harvested from both log-phase and confluent cultures. There was little impact of stage of culture on assay results. Finally, because test compounds are routinely prepared in DMSO, the effects of DMSO on cell viability and signal generation were examined. The data indicated that assay cell line proliferation, viability, and signal were unaffected by DMSO concentrations ranging from 0% to 3% (data not shown). 
Positive control and assay performance
Along with the compounds mentioned in the "Materials and Methods" section, the HIF-1 inhibitors NSC606985, camptothecin, geldanamycin, 17-AAG, ibuprofen, resveratrol, luteolin, and quercetin as well as non-HIF-specific inhibitors cycloheximide, LY294-002, and rapamycin were evaluated as potential assay controls. Although these compounds showed inhibition of reporter activity in the HRE reporter lines, none of these compounds were found to show selective inhibition of HIF-2-dependent luciferase activity. Moreover, constitutively driven reporter activity was found to be equally inhibited by these compounds. In addition, inhibition of reporter activity by these compounds was found to correlate with a high degree of cytotoxicity. Although not a specific HIF-2 inhibitor, actinomycin D was found to attenuate reporter activity at a concentration of 0.5 µg/mL with a much lower level of cytotoxicity. To determine the half-life of the reporter protein, cells were plated at a seeding density of 2500, 5000, and 10,000 cells per well in a 384-well plate and incubated with 1, 0.5, and 0.1 µg/mL of actinomycin D for up to 48 h. Luciferase activity was measured at various time intervals, while cell viability was also assessed in parallel at these intervals. As shown in Figure 5 (data shown for seeding density of 5000 cells/well), reduction of luciferase activity was significant only after 7 h of incubation, and then reporter activity decreased to about 50% after incubation of 20 h. Significant cytotoxic effects by the test compound appeared only after 30 h of incubation. As a result, actinomycin D was selected for use as a positive assay control whereas the length of incubation with test compounds in the screen was set to 24 to 30 h.
To assess the robustness of the assay protocol in a microplate format, a study was run over 2 days with 3 plates per day. Plate uniformity, signal-to-noise ratio, and Z′ factor were assessed using 1% DMSO (screening concentration). The utility of the assay for HTS was demonstrated by its reproducibility with an average Z′ value of 0.63 using the assay positive control (actinomycin D), which showed moderate inhibition of the reporter activity ( Fig. 6) . Examination of the data for plate uniformity also revealed that the assay is compatible with the automation used in cell plating and liquid handling, as minimal drift and edge effects were observed in plate readouts (Fig. 6) .
Screening strategy
A schematic representation of the envisioned HTS campaign is as shown in Figure 7 . Initial screening of our library of compounds and extracts will take place using the 786-O 5xVHRE-Luc cell line. Here, compounds inhibiting luciferase activity will be chosen as hits. In phase 2 of the screen, hits will be evaluated using the 786-O LLuc line to exclude compounds inhibiting luciferase expression in a nonspecific, HIF-independent manner. In this phase, toxicity and inhibition of cell growth by hits will be assessed in an XTT-based colorimetric assay 28 to determine the contribution of cytotoxic effects in the inhibition of reporter activity. In phase 3, phase 2 hits are tested against the 786-O 5xNHRE-Luc cell line to identify compounds that inhibit HIF-2 in general and not just in a VEGF-specific manner. In phase 4 of the screen, hits from phase 3 are finally screened using the MDA-MB-435 5xVHRE-Luc cell line to determine whether they also inhibit reporter expression driven by HIF-1. Here, the HIF-2 versus the HIF-1 selectivity index will be used to further rank compounds of interest.
In vivo imaging
Studies were also performed with the luciferase reporter cell lines to evaluate luminescent imaging as a measure of the in vivo efficacy of HIF-2 inhibitor compounds identified by the assay. In vivo imaging experiments were performed using SCIDbeige mice inoculated with 1 × 10 6 cells subcutaneously (s.c.), intrarenally (i.r.), or through the intra-tail vein (i.t.v.). Tumor progression was monitored for 2 mo and was found to be measurable using luminescent imaging. As representative images shown in Figure 8 indicate, the use of cell lines transformed with luciferase constructs will enable further testing of hits in vivo in different mouse models. In addition, these reporter cell lines could potentially be used in imaging of hypoxic regions in renal cell carcinoma tumor models in vivo as was demonstrated using an HRE-luciferase reporter line for HIF-1. 29
CONCLUSION
We have engineered stably transformed luciferase reporter cell lines for use in HTS aimed at identifying inhibitors of HIF-2. Their utility in the assay was demonstrated by reintroduction of VHL and exposure to hypoxia, which confirmed reporter inducibility by HIF-2. The wide dynamic range in reporter activity, tolerance to DMSO, and high signal-to-noise ratio confirmed their suitability for HTS. We have also demonstrated their potential use in an in vivo evaluation of hits from the HTS campaign.
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FIG. 7.
Schematic representation of a screening program to identify small-molecule inhibitors of hypoxia-inducible factor 2 (HIF-2)induced gene expression. Luciferase reporter activity in vascular endothelial growth factor-and human endothelial nitric oxide synthasehypoxia response element-containing 786-O lines is measured as a readout for HIF activity in phases 1 and 3. Inhibition of HIF-independent reporter expression by phase 1 hits is tested in phase 3 using a 786-O line constitutively expressing luciferase. Selective HIF-2 activity by phase 3 hits is then evaluated in the cell line MDA-MB-435, which expresses HIF-1 only.
